IMU product line - HER-Vaxx, page-22

I wrote to IMU last week regarding Her-vaxx. As the removal of HER-Vaxx from the presentation slides at the latest AGM, combined with no forthcoming updates forQ4 2023 and 2024, (as detailed in the slides in November 2023) was particularly disconcerting for me. Given the historical emphasis on HER-Vaxx's role in IMU’s portfolio and the lack of clear communication, i wanted to understand what is the future of this once-promising therapy.

IMU’sresponse to me is as follows:

HER-Vaxx have been de-prioritised behind theAzer-cel and OnCARlytics programs. HER-Vaxx is an active candidate forout-licensing and we will continue that business development strategy in2024. Out-licensing is a complex business and takes time so it isnot possible to put a time frame on it. We are unable to provide specifictimelines since this is market sensitive information.

Recruitment has ceased on the IMPRINTERtrial. PD1-Vaxx is now progressing in colorectal cancers (CRC) in a Phase2 study in earlier lines of disease (pre-surgery). The pivot away fromNSCLC to CRC has been made to maximise the potential of PD1-Vaxx forearlier data read outs and for registrational pathways for our product.

Is Her-vaxx dead? I suspect it is. I certainly doubt we will be seeing any good news about this prior to Christmas or even next Christmas.